Gepants are a class of oral small-molecule CGRP receptor antagonists used for acute and (in two cases) preventive migraine treatment. The first gepant approval was 2019; the class is now four members in the US market.
Gepants are part of the broader CGRP-targeting therapy revolution, but distinct from the monoclonal antibodies. Where the antibodies are large protein injectables given monthly or quarterly for prevention, gepants are small molecules taken orally — either for acute attacks or daily/ alternate-day prevention.
The four approved gepants
| Drug | Brand | Indication | Dosing |
|---|---|---|---|
| Ubrogepant | Ubrelvy | Acute treatment | 50 or 100 mg PO at attack onset, repeat in 2h if needed |
| Rimegepant | Nurtec ODT | Acute + prevention | 75 mg ODT at attack onset OR every other day for prevention |
| Atogepant | Qulipta | Prevention | 10, 30, or 60 mg PO daily |
| Zavegepant | Zavzpret | Acute treatment | 10 mg nasal spray |
Rimegepant is unique in carrying both acute and preventive indications — a single drug that works in both roles.
Mechanism
CGRP (calcitonin gene-related peptide) is a neuropeptide released from trigeminal nerve endings during migraine attacks. It causes vasodilation, sensitises pain pathways, and contributes to neurogenic inflammation.
Gepants block the CGRP receptor — preventing CGRP from signalling once released. The result: reduced vasodilation, reduced pain sensitisation, reduced inflammation. The acute attack response is comparable to triptans in efficacy without the vasoconstriction mechanism.
Why gepants matter clinically
Three significant advantages over the triptan class:
1. No cardiovascular contraindications
Triptans constrict vessels — including coronary vessels — making them inappropriate for patients with known coronary artery disease, prior stroke, uncontrolled hypertension, or peripheral vascular disease. Roughly 15–20 percent of adult migraine patients have some cardiovascular contraindication that limits triptan use.
Gepants don’t constrict vessels, so they’re safer in these populations. This single change opens an acute treatment option to a large subset of patients who previously had limited choices.
2. No medication overuse headache (so far)
Current evidence suggests gepants do not cause MOH at the same thresholds as triptans (≥ 10 days/month) or simple analgesics (≥ 15 days/month). This is a real advantage for high-frequency users.
The “so far” caveat is important — gepants are new (2019+ approvals) and long-term data is still accumulating. Current MOH absence may be a true class effect or may simply be that we haven’t watched long enough to see it. Most prescribers treat gepants as MOH-neutral in practice.
3. Prodrome-phase efficacy
The 2023 PRODROME trial (Lancet) tested ubrogepant taken during the prodromal phase — before headache pain began — against placebo. Result: significantly fewer participants in the treatment group progressed to moderate-or-severe headache in the following 24 hours.
This is the first solid evidence for pre-pain treatment with any acute migraine drug class. Triptans haven’t been tested rigorously in this regime; the receptor pharmacology of gepants may be particularly well-suited to prodromal intervention.
The trade-offs
Gepants aren’t superior to triptans in every dimension:
- Cost — gepants are substantially more expensive than generic triptans. Insurance prior authorisation often requires failure of triptan first.
- Onset speed — gepants take longer to peak effect than injectable triptans (though comparable to oral triptans).
- Established track record — triptans have 30+ years of use; gepants have 5+. Some clinical edges of the long experience aren’t yet known for gepants.
For most patients without cardiovascular contraindications, the triptan-first then gepant-if-needed approach remains the typical prescribing pattern in 2026.
Where gepants fit
The 2026 acute treatment hierarchy for most patients:
- Triptan (if cardiovascular-safe) — first-line for moderate acute migraine.
- Gepant — when triptan ineffective, intolerable, or contraindicated.
- Combination/NSAID — for milder attacks or as adjunct.
For prevention:
- CGRP monoclonal antibody (Aimovig, Ajovy, Emgality, Vyepti) — first-line CGRP-class preventive for most prescribers in 2026.
- Atogepant or rimegepant — oral CGRP preventive option, particularly when the patient prefers a pill or has needle aversion.
- Traditional preventives (topiramate, beta blockers, amitriptyline, valproate) — still used, particularly for patients with comorbidities the drugs also treat (e.g., topiramate for migraine + weight loss concerns).
What this isn’t
Not a recommendation that any patient should switch from triptans to gepants. The right choice depends on individual cardiovascular history, attack pattern, prior medication response, insurance coverage, and prescriber preference. That conversation lives with your headache specialist or neurologist.